Seagen Inc. (SGEN)
SGEN moved a median of -0.01% 30 minutes after news, and +0.13% by the close. How SGEN actually reacts to news — the realized, point-in-time move the market made, measured across 62 labeled events over the last three years with zero look-ahead.
SGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 29 |
| 30-min | -0.01% | 48% | 29 |
| 60-min | +0.06% | 59% | 29 |
| to close | +0.13% | 59% | 29 |
| Middle 50% of SGEN reactions | -0.14% to +0.23% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 62 |
Half of all Seagen Inc. news events land between -0.14% and +0.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SGEN's baseline. Nothing else.
Recent SGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Seagen Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer | Press release | PR Newswire | — | — | |
| Form 8-K Seagen Inc. For: Dec 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POSASR Seagen Inc. | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Seagen Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Seagen Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +0.02% | |
| ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma | Press release | Business Wire | -0.19% | +0.73% | |
| TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer | Press release | Business Wire | -0.23% | -0.14% | |
| FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer | Press release | Business Wire | -0.23% | -0.41% | |
| Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Press release | Business Wire | -0.01% | -0.20% | |
| New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate | Press release | Business Wire | +0.00% | +0.06% | |
| Form 10-Q Seagen Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.23% | +0.41% | |
| Form 8-K Seagen Inc. For: Nov 01 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | +0.41% | |
| Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress | Press release | Business Wire | +0.23% | +0.41% | |
| Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer | Press release | Business Wire | -0.37% | +0.13% | |
| TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial | Press release | Business Wire | -0.37% | +0.13% | |
| Form 8-K Seagen Inc. For: Oct 19 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | +0.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SGEN section they belong to.
Where else SGEN is measured.
SGEN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PLANDAI BIOTECHNOLOGY INC (PLPL) | 62 | 0.00% | 41% |
| Biosyent Inc (RX_CDNX) | 62 | 0.00% | 33% |
| THERAPEUTIC SLTNS INTL (TSOI) | 62 | 0.00% | 28% |
| GREEN CURES & BOTANICAL (GRCU) | 61 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Seagen Inc.'s median reaction calculated?
Every labeled SGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 62 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of SGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.